Warning: There are an increasing number of fraudulent websites and emails that impersonate FENS. We would like to alert all our members, delegates, and exhibitors to possible scams. We strongly advise you to use only the official FENS online registration and accommodation for your bookings, and not to trust emails offering attendee lists.

Mini Conferences

Jul
09

MC04 – What is the mode of action of serotonin psychedelics in brain disorders? – Organised by ‎European College of Neuropsychopharmacology (ECNP) (09:00-15:00)

Psychedelics such as psilocybin (‘magic mushrooms’), LSD and ayahuasca have lately gained renewed attention as
novel therapeutics for neuropsychiatric disorders such as depression, anxiety, obsession and addiction. The experts will cover a spectrum of topics from basic neuroscience to novel neuroimaging techniques in studies of humans under influence of psychedelics.

By |
DETAIL
Jul
09

MC03 -Sleep regulation and functions: when the periphery talks to the brain – Organised by European Sleep Research Society (ESRS)/French Society for Sleep Research and Sleep Medicine (SFRMS) (09:00-15:00)

The ESRS and SFRMS host a mini-conference on “sleep regulation and functions” at the FENS forum in Paris on July 9th from 9:00 to 15:00. Interested to attend this event?
Please register

By |
DETAIL
Jul
09

MC02 – Molecular basis for synaptic function highlighting disease mechanisms – Organised by European Society for Neurochemistry (ESN) (09:00-15:00)

There are currently hardly any disease modifying treatments for neurodevelopmental or neurodegenerative diseases presenting malfunctioning synaptic connections. Our Mini- Conference will highlight novel aspects of genes and behavior toward better therapeutics.

By |
DETAIL
Jul
09

MC01 – Understanding behaviour: Molecular, cellular & systems approaches. Organised by: EBPS, EBBS, EMCCS & IBANGS (09:00-13:20)

Theoretical and technical advances to deconvolute and understand the various mechanisms which underpin brain
function and behaviour in model organisms are critical to developing new therapies for CNS disorders.

By |
DETAIL